US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan

By afschroeder • August 6, 2025

Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney S, Treister NS, Matthews C, Johnson M. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Support Care Cancer. 2025 Aug 5;33(9):756. doi: 10.1007/s00520-025-09805-y. PMID: 40762824.

Tags: adverse event management, consensus, Dato-DXd, Dexamethasone mouthwash, Hematology/Oncology, oral mucositis, Publications, stomatitis

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement

Llovet JM, Mauro E, Rimassa L, Mazzaferro V, Pinter M, Kelley RK, Chan SL, Kulik L, Pillai A, Roberts L, Sangro B, Casanovas T, Kaplan[...]

Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1

Lim A, Peluso EM, Downs IA, Horwich BH, Velez-Velez MA, Lechner MG. Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome[...]

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial)

Kirtane K, Niu J, Blumenschein G, Massarelli E, Hanna GJ, Lee S, Bishop MR, Konecny GE, Mao D, Zheng Y, Rodriguez K, Kim JJ, Williams[...]